Key result
Elevated serum S100A12 is independently linked to ACS versus stable CAD and normal arteries.
Why the study?
Are serum S100A8, S100A9, and S100A12 levels associated with acute coronary syndrome in patients undergoing coronary angiography?
Observational (n=90)
Are serum S100A8, S100A9, and S100A12 levels associated with acute coronary syndrome in patients undergoing coronary angiography?
Serum S100A12 is significantly elevated in patients with acute coronary syndrome and may serve as a biomarker for coronary plaque instability.
Answers are grounded in this paper and cite their sources.
May support S100A12 as ACS biomarker candidate; leaves open clinical utility pending prospective validation.
AIMS: In this study, we aimed to investigate whether serum S100A8, S100A9 and S100A12 levels were markers of acute coronary syndrome (ACS). MATERIALS & METHODS: Patients who underwent coronary angiography and/or percutaneous coronary interventions between June 2015-October 2015 were consecutively recruited in this study and categorized three groups each containing 30 patients (normal coronary arteries, stable coronary artery disease, and acute coronary syndrome). Baseline characteristics, including co- morbidities and medications, were recorded and serum S100A8, S100A9, S100A12, and C- reactive protein levels were measured besides routine laboratory tests. RESULTS: A total of 90 patients (63.00 [56.00-73.00] years, 62.89% male) have been included. None of the groups differed from each other regarding baseline characteristics (p > 0.05). S100A9 levels were elevated in ACS when compared with the normal coronary arteries (p = 0.033) and S100A12 levels were found to be elevated in ACS when compared with both patients with normal coronary arteries and stable coronary artery disease (p = 0.001). S100A12 was identified as an independent associate of ACS (p = 0.002). CONCLUSION: These results suggest that S100A12 may serve as a marker of coronary plaque instability, and may have a therapeutic implication in ACS treatment.
No takes yet. Share an insight, caveat, or question.
Büyükterzi et al. (2017) conducted an observational in Acute coronary syndrome (n=90). Serum S100A8, S100A9, and S100A12 levels vs. Normal coronary arteries and stable coronary artery disease was evaluated on Association with acute coronary syndrome (p=0.002). Serum S100A12 levels were significantly elevated in acute coronary syndrome compared to normal coronary arteries and stable CAD (p=0.001), and independently associated with ACS (p=0.002).
Synapse has enriched 10 related papers. Consider them for comparative context: